This week’s Immunology update highlights regulatory approvals, advancing late- and mid-stage clinical data, genetics research insights, and continued portfolio expansion through strategic acquisitions.
In Today’s Newsletter
Dive deeper
💊 Utebzi FDA approval for complicated urinary tract infections [1] [US • 17 Jun 2026]
https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-complicated-urinary-tract-infections-cutis/
Context: GSK and Spero Therapeutics received FDA approval for Utebzi (tebipenem pivoxil), an oral carbapenem for eligible adults with cUTIs, including pyelonephritis.
Key point: PIVOT-PO showed non-inferiority versus IV imipenem-cilastatin, with overall success of 58.5% versus 60.2%.
Implication: Introduces competition that may affect pricing and formulary access.
🧬 Pediatric pancreatitis risk variants tied to progression [2] [17 Jun 2026]
https://scienceblog.cincinnatichildrens.org/largest-pediatric-pancreatitis-genetics-study-identifies-risk-variants-tied-to-disease-progression/
Context: Cincinnati Children’s, INSPPIRE, and CPCRC analyzed genetic data from 944 children with acute recurrent pancreatitis or chronic pancreatitis.
Key point: 74% carried at least one focused genetic risk variant, and children with variants progressed faster to chronic pancreatitis.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
🧫 Odyssey OD-001 Phase 2a UC proof-of-concept [3] [17 Jun 2026]
https://investors.odysseytx.com/news-releases/news-release-details/odyssey-therapeutics-reports-first-quarter-2026-financial
Context: OD-001 (Odyssey Therapeutics; oral RIPK2 scaffolding inhibitor) was tested for 12 weeks in a Phase 2a monotherapy study in moderate-to-severe UC.
Key point: Among 49 efficacy-evaluable patients, 27% achieved clinical remission and 61% achieved clinical response.
Implication: May influence prescriber choice and payer reviews pending full data.
🤝 Biogen to acquire RayThera immunology assets [4] [17 Jun 2026]
https://investors.biogen.com/news-releases/news-release-details/biogen-expands-immunology-pipeline-agreement-acquire-raythera
Context: Biogen agreed to acquire RayThera, a private immunology company with small-molecule anti-inflammatory assets.
Key point: Deal value is up to $1 billion, with a lead candidate expected to enter Phase 1 in early Q3 2026.
Implication: Signals pipeline investment and modality expansion.
🧴 Derm-Biome DB-006 pre-clinical atopic dermatitis data [5] [19 Jun 2026]
https://www.dermatologytimes.com/view/topical-db-006-shows-strong-efficacy-safety-in-preclinical-ad-model
Context: Derm-Biome reported pre-clinical DB-006 data in an atopic dermatitis model, with no clinical timeline disclosed.
Key point: DB-006 reportedly reduced itch, epithelial thickening, inflammation, and IgE, with antimicrobial activity against Staphylococcus aureus.
Implication: May influence prescriber choice and payer reviews pending full data.
🛡️ Merck tulisokibart Phase 3 ATLAS-UC topline [6] [22 Jun 2026]
https://www.merck.com/news/mercks-tulisokibart-met-primary-and-key-secondary-endpoints-in-the-phase-3-atlas-uc-induction-only-study-in-patients-with-moderately-to-severely-active-ulcerative-colitis-uc/
Context: Tulisokibart (Merck; anti-TL1A monoclonal antibody) was evaluated in Phase 3 ATLAS-UC Study 2 for moderately-to-severely active UC.
Key point: The induction-only study met clinical remission by Modified Mayo Score at week 12 and key secondary endpoints.
Implication: May influence prescriber choice and payer reviews pending full data.
🧪 AbbVie to acquire Apogee Therapeutics [7] [US • 22 Jun 2026]
https://news.abbvie.com/2026-06-22-AbbVie-to-Acquire-Apogee-Therapeutics,-Deepening-Immunology-Portfolio
Context: AbbVie agreed to acquire Apogee Therapeutics, adding immunology assets in atopic dermatitis, asthma, and related inflammatory diseases.
Key point: AbbVie will pay $135.11 per share in cash, valuing Apogee at about $10.9 billion.
Implication: Signals pipeline investment and modality expansion.
Why it matters
- Oral anti-infective options are expanding into high-need resistant-infection settings, with Utebzi positioned as a US outpatient alternative to IV carbapenems. [1]
- Pediatric pancreatitis genetics may support broader testing and earlier risk stratification in recurrent or chronic disease. [2]
- TL1A and RIPK2 remain active ulcerative colitis mechanisms, with Merck and Odyssey moving clinical evidence forward. [3], [6]
- Immunology dealmaking remains strong, with Biogen and AbbVie adding assets across small molecules, antibodies, dermatology, and respiratory disease. [4], [7]
- Pre-clinical topical AD candidates are emphasizing itch, inflammation, barrier pathology, and S. aureus biology. [5]
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 View the full Immunology archive on our research hub page.
FAQ
What is Utebzi, and who is it for?
Utebzi (tebipenem pivoxil; GSK and Spero Therapeutics) is an oral carbapenem approved by the FDA for eligible adults with cUTIs, including pyelonephritis, who have limited or no alternative oral options. [1]
What did the pediatric pancreatitis genetics study find?
Cincinnati Children’s and collaborators found that 74% of 944 children carried at least one focused genetic risk variant, and variant carriers progressed faster to chronic pancreatitis. [2]
What is OD-001 in ulcerative colitis?
OD-001 (Odyssey Therapeutics) is an oral RIPK2 scaffolding inhibitor. In Phase 2a UC data, 49 patients were efficacy-evaluable after 12 weeks. [3]
Why is tulisokibart notable in ulcerative colitis?
Tulisokibart (Merck; anti-TL1A) met the primary endpoint of clinical remission at week 12 in Phase 3 ATLAS-UC Study 2, with no safety concerns identified in the topline release. [6]
What does AbbVie get from Apogee Therapeutics?
AbbVie adds zumilokibart (APG777), a half-life extended IL-13 antibody in AD, plus APG273, a long-acting IL-13 and TSLP combination being developed in asthma. [7]
Entities / Keywords
Utebzi, tebipenem pivoxil, GSK, Spero Therapeutics, cUTI, pyelonephritis, oral carbapenem, PIVOT-PO
Cincinnati Children’s, INSPPIRE, CPCRC, pediatric pancreatitis, PRSS1, CFTR, SPINK1, CTRC, CASR, CPA1
Odyssey Therapeutics, OD-001, RIPK2 scaffolding inhibitor, ulcerative colitis, OD-002, SLC15A4
Biogen, RayThera, immunology, small-molecule anti-inflammatory assets, Phase 1
Derm-Biome Pharmaceuticals, DB-006, atopic dermatitis, S. aureus, IgE, pruritus
Merck, MSD, tulisokibart, MK-7240, TL1A, ATLAS-UC, Modified Mayo Score
AbbVie, Apogee Therapeutics, zumilokibart, APG777, APG273, APG333, IL-13, TSLP, asthma
References
- https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-complicated-urinary-tract-infections-cutis/
- https://scienceblog.cincinnatichildrens.org/largest-pediatric-pancreatitis-genetics-study-identifies-risk-variants-tied-to-disease-progression/
- https://investors.odysseytx.com/news-releases/news-release-details/odyssey-therapeutics-reports-first-quarter-2026-financial
- https://investors.biogen.com/news-releases/news-release-details/biogen-expands-immunology-pipeline-agreement-acquire-raythera
- https://www.dermatologytimes.com/view/topical-db-006-shows-strong-efficacy-safety-in-preclinical-ad-model
- https://www.merck.com/news/mercks-tulisokibart-met-primary-and-key-secondary-endpoints-in-the-phase-3-atlas-uc-induction-only-study-in-patients-with-moderately-to-severely-active-ulcerative-colitis-uc/
- https://news.abbvie.com/2026-06-22-AbbVie-to-Acquire-Apogee-Therapeutics,-Deepening-Immunology-Portfolio